Filing Details
Prelude Therapeutics Inc (NASDAQ:PRLD) filed a Form 8-K with the Securities and Exchange Commission on August 11, 2026, disclosing a material event.
8k filedNASDAQ:PRLD
Prelude Therapeutics Inc (PRLD) Reports Material Event to SEC
Prelude Therapeutics Inc (NASDAQ:PRLD) filed a Form 8-K with the Securities and Exchange Commission on August 11, 2026, disclosing a material event.
At publication ·
What changed
Prelude Therapeutics Inc (NASDAQ:PRLD) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Prelude Therapeutics Inc filed a Form 8-K with the SEC on August 11, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this article.
- The company's stock trades at $5.32 with a market capitalization of $89.1 million as a healthcare company.
- Form 8-K filings report material events such as leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance that occur between regular quarterly or annual reports.
Market Context
Prelude Therapeutics Inc's stock currently trades at $5.32 with a market capitalization of $89.1M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Prelude Therapeutics Inc's stock.
All SEC filings for Prelude Therapeutics Inc are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View PRLD Stock Page
Frequently Asked Questions
Where can I read PRLD's SEC filings?
Browse all filings on our PRLD SEC filings page.
What types of SEC filings does Prelude Therapeutics Inc file?
Public companies like Prelude Therapeutics Inc file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.